# Samsung Biologics Secures 87.9% Stake in PolyPeptide Group Tender Offer

- URL: https://stocks.freetheai.org/news/samsung-biologics-secures-87-9-stake-in-polypeptide-group-tender-offer-3221bd
- Published: 2026-10-13T05:10:05Z
- Category: mergers; sentiment: bullish; impact: high
- Symbols: [BX:8H0](https://stocks.freetheai.org/symbols/BX-8H0), [KRX:207940](https://stocks.freetheai.org/symbols/KRX-207940)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Samsung Biologics Co., Ltd. (KRX:207940) has secured a controlling majority in its public takeover bid for Swiss contract development and manufacturing firm PolyPeptide Group AG (BX:8H0). Through its direct subsidiary Samsung Peptide AG, the company announced that 29,014,418 PolyPeptide shares were tendered during the main offer period ending October 12, 2026. This brings total participation by Samsung Peptide and concert parties to 29,123,892 shares, representing 87.92% of PolyPeptide's issued share capital and voting rights.

The provisional results satisfy key offer conditions, including the minimum acceptance threshold and the absence of material adverse changes. The successful main offer period marks a significant step for Samsung Biologics in expanding its biomanufacturing capabilities and footprint into specialized peptide-based active pharmaceutical ingredients.

Definitive interim results are expected on October 16, 2026. Subject to confirmation, an additional 10-trading-day acceptance period for remaining shareholders will run from October 19 to October 30, 2026. PolyPeptide shareholders will also vote at an extraordinary general meeting on October 26, 2026, on board nominations and the removal of voting restrictions, while regulatory approvals in select jurisdictions remain pending.

## Key points

- Samsung Biologics achieved an 87.92% total participation rate in its public tender offer for PolyPeptide Group AG.
- A total of 29,014,418 shares were tendered during the main offer period that ended October 12, 2026.
- Key deal conditions regarding minimum acceptance rates and material adverse effects have been satisfied.
- PolyPeptide shareholders will vote on board nominees and voting restriction removals at an October 26 meeting.
- An additional ten-day acceptance period for remaining shareholders is scheduled for October 19 through October 30.

## Questions and answers

### What percentage of PolyPeptide shares were tendered to Samsung Biologics?

Shareholders tendered 29,014,418 shares during the main offer period, representing 87.59% of PolyPeptide's share capital. Total participation by Samsung Biologics and concert parties reached 87.92% (29,123,892 shares).

### When is the additional acceptance period for the PolyPeptide tender offer?

If the offer is declared successful in the definitive notice, the additional acceptance period will run for ten trading days from October 19, 2026, to October 30, 2026, at 4:00 p.m. Swiss time.

### What are the next steps for Samsung Biologics' acquisition of PolyPeptide?

Definitive results will be released on October 16, 2026. PolyPeptide has scheduled an extraordinary general meeting for October 26, 2026, to vote on board nominees and removing transfer and voting restrictions. The deal also awaits regulatory approvals.